Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

798 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of tolvaptan on the prognosis of patients with hepatic ascites.
Hiramine Y, Uto H, Mawatari S, Kanmura S, Imamura Y, Hiwaki T, Saishoji A, Yada T, Inada Y, Sakamoto H, Higashi H, Kubozono O, Maenohara S, Ido A. Hiramine Y, et al. Among authors: inada y. Hepatol Res. 2019 Jul;49(7):765-777. doi: 10.1111/hepr.13337. Epub 2019 Apr 30. Hepatol Res. 2019. PMID: 30916842
Viral and host factors are associated with retreatment failure in hepatitis C patients receiving all-oral direct antiviral therapy.
Mawatari S, Oda K, Kumagai K, Tabu K, Ijuin S, Fujisaki K, Inada Y, Uto H, Saisyoji A, Hiramine Y, Hori T, Taniyama O, Toyodome A, Sakae H, Hashiguchi M, Kure T, Sakurai K, Tamai T, Moriuchi A, Ido A. Mawatari S, et al. Among authors: inada y. Hepatol Res. 2020 Apr;50(4):453-465. doi: 10.1111/hepr.13474. Epub 2020 Jan 16. Hepatol Res. 2020. PMID: 31846553
Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals.
Tabu K, Mawatari S, Oda K, Kumagai K, Inada Y, Uto H, Saisyoji A, Hiramine Y, Hashiguchi M, Tamai T, Hori T, Fujisaki K, Imanaka D, Kure T, Taniyama O, Toyodome A, Ijuin S, Sakae H, Sakurai K, Moriuchi A, Kanmura S, Ido A. Tabu K, et al. Among authors: inada y. PLoS One. 2020 Aug 13;15(8):e0237475. doi: 10.1371/journal.pone.0237475. eCollection 2020. PLoS One. 2020. PMID: 32790728 Free PMC article.
Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus.
Mawatari S, Kumagai K, Oda K, Tabu K, Ijuin S, Fujisaki K, Tashima S, Inada Y, Uto H, Saisyoji A, Hiramine Y, Hashiguchi M, Tamai T, Hori T, Taniyama O, Toyodome A, Sakae H, Kure T, Sakurai K, Moriuchi A, Kanmura S, Ido A. Mawatari S, et al. Among authors: inada y. PLoS One. 2022 Jan 12;17(1):e0262267. doi: 10.1371/journal.pone.0262267. eCollection 2022. PLoS One. 2022. PMID: 35020772 Free PMC article.
New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir.
Mawatari S, Oda K, Tabu K, Ijuin S, Kumagai K, Inada Y, Uto H, Hiramine Y, Kure T, Fujisaki K, Hashiguchi M, Hori T, Oshige A, Imanaka D, Saishoji A, Taniyama O, Sakae H, Tamai T, Moriuchi A, Ido A. Mawatari S, et al. Among authors: inada y. J Gastroenterol. 2017 Jul;52(7):855-867. doi: 10.1007/s00535-016-1303-0. Epub 2017 Jan 11. J Gastroenterol. 2017. PMID: 28078469
The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir.
Mawatari S, Oda K, Tabu K, Ijuin S, Kumagai K, Fujisaki K, Hashiguchi M, Inada Y, Uto H, Hiramine Y, Kure T, Hori T, Taniyama O, Kasai A, Tamai T, Moriuchi A, Ido A. Mawatari S, et al. Among authors: inada y. PLoS One. 2018 Jun 1;13(6):e0198642. doi: 10.1371/journal.pone.0198642. eCollection 2018. PLoS One. 2018. PMID: 29856885 Free PMC article.
Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
Akuta N, Toyota J, Karino Y, Ikeda F, Ido A, Tanaka K, Takaguchi K, Naganuma A, Tomita E, Chayama K, Fujiyama S, Inada Y, Yoshiji H, Watanabe H, Ishikawa H, McPhee F, Noviello S, Kumada H. Akuta N, et al. Among authors: inada y. J Gastroenterol. 2018 Sep;53(9):1089-1097. doi: 10.1007/s00535-018-1445-3. Epub 2018 Mar 2. J Gastroenterol. 2018. PMID: 29500489
Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.
Toyota J, Karino Y, Suzuki F, Ikeda F, Ido A, Tanaka K, Takaguchi K, Naganuma A, Tomita E, Chayama K, Fujiyama S, Inada Y, Yoshiji H, Watanabe H, Ishikawa H, Hu W, McPhee F, Linaberry M, Yin PD, Swenson ES, Kumada H. Toyota J, et al. Among authors: inada y. J Gastroenterol. 2017 Mar;52(3):385-395. doi: 10.1007/s00535-016-1245-6. Epub 2016 Aug 9. J Gastroenterol. 2017. PMID: 27502287 Clinical Trial.
A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3.
Foster GR, Chayama K, Chuang WL, Fainboim H, Farkkila M, Gadano A, Gaeta GB, Hézode C, Inada Y, Heo J, Kumada H, Lu SN, Marcellin P, Moreno C, Roberts SK, Strasser SI, Thompson AJ, Toyota J, Paik SW, Vierling JM, Zignego AL, Cohen D, McPhee F, Wind-Rotolo M, Srinivasan S, Hruska M, Myler H, Portsmouth SD. Foster GR, et al. Among authors: inada y. Springerplus. 2016 Aug 19;5(1):1365. doi: 10.1186/s40064-016-2920-z. eCollection 2016. Springerplus. 2016. PMID: 27588258 Free PMC article.
798 results